CSPC Pharmaceutical Group Limited has announced a strategic research collaboration agreement with AstraZeneca, a global leader in biopharmaceuticals, to discover and develop novel oral small molecule candidates. The agreement will utilize CSPC's AI-driven, dual-engine efficient drug discovery platform to identify promising small molecules targeting multiple diseases. AstraZeneca will have the option to exclusively license the pre-clinical candidates for development, manufacturing, and commercialization worldwide. CSPC will receive an upfront payment of $110 million, with potential additional payments totaling up to $1,620 million for development milestones and $3,600 million for sales milestones, along with possible royalties based on annual net sales.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。